September 21, 2018 Bio/Pharma/CRO

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia

Basel, 21 September 2018 Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Positive CHMP recommendation based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by... Read more

September 18, 2018 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer

Basel, 18 September 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer Agenda Roche lung cancer portfolio key data IMpower133: Primary PFS, OS, and Safety in a Ph1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in... Read more

September 18, 2018 Clinical Research/Diagn.

Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases

Basel, 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalised treatment decisions by oncology care teams Roche (SIX:... Read more

September 13, 2018 Acad, Gov/Utilities Microscopy

FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis

Basel, 13 September 2018 FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active... Read more

September 13, 2018 Bio/Pharma/CRO

Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running

Basel, 13 September 2018 Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running Sustainability is an integral part of Roche’s business strategy The company performed particularly well in Marketing Practices, Environmental and Social Reporting and Health Outcome Contribution For the tenth consecutive year, Roche (SIX: RO,... Read more

September 6, 2018 Bio/Pharma/CRO

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC

Basel, 06 September 2018 Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC Roche (SIX: RO, ROG; OTCQX: RHHBY). On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ® (atezolizumab)... Read more

September 6, 2018 Bio/Pharma/CRO

Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)

Basel, 06 September 2018 Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the TECENTRIQ lung programme, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer New... Read more

September 3, 2018 Bio/Pharma/CRO PR/Corporate

Reminder: Invitation to Roche's Virtual Late Stage Pipeline Event 2018

Basel, 03 September 2018 Reminder: Invitation to Roche’s Virtual Late Stage Pipeline Event 2018 We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio.   The Roche Virtual Late Stage Pipeline Event... Read more

August 30, 2018 Bio/Pharma/CRO

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more